Increlex mecasermin regulatory update

FDA approved an NDA for Increlex mecasermin for the long-term treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. ...